Literature DB >> 9726050

Partial regression in primary carcinoma of the lung: does it occur?

K M Kerr1, S K Johnson, G King, M M Kennedy, J Weir, R Jeffrey.   

Abstract

AIMS: To study immunohistochemically a group of 28 primary lung cancers which demonstrated histological features reminiscent of those characteristic of regression in malignant melanoma, to determine the phenotype of their immune cell infiltrates. METHODS AND
RESULTS: Using a standard s-ABC immunoperoxidase method then quantification by the Leica Q500 MC image analyser, the cellular infiltrate in these tumours, when compared to 67 control cases, showed excess CD3 + T lymphocytes (P < 0.007), with an increase in CD4:CD8 ratio and increased CD68 + macrophages (P = 0.00001). CD57 + natural killer cells and S100 + Langerhans cells were also increased, but not quite significantly (P = 0.048 and P = 0.072, respectively).
CONCLUSIONS: This immunophenotype resembles that shown in regressing skin malignancies and suggests a similar process occurring in lung cancer. Regressing lung cancers are associated with a better prognosis than matched controls (P = 0.0034), some showed radiological evidence of growth retardation and the group had an excess of the large cell undifferentiated histological type.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9726050

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  11 in total

Review 1.  Differential macrophage programming in the tumor microenvironment.

Authors:  Brian Ruffell; Nesrine I Affara; Lisa M Coussens
Journal:  Trends Immunol       Date:  2012-01-23       Impact factor: 16.687

2.  Alveolar macrophage function is altered in patients with lung cancer.

Authors:  D S Pouniotis; M Plebanski; V Apostolopoulos; C F McDonald
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 3.  One microenvironment does not fit all: heterogeneity beyond cancer cells.

Authors:  Ik Sun Kim; Xiang H-F Zhang
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

4.  Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting.

Authors:  Thaer Khoury; Saif Aljabab; Song Yao; Christine Ambrosone; Angela Omilian; Kristopher Attwood; Wenyan Ji; Shipra Gandhi
Journal:  Breast Cancer Res Treat       Date:  2022-06-18       Impact factor: 4.624

Review 5.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 6.  The anticancer immune response: indispensable for therapeutic success?

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

7.  Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma.

Authors:  Raphael Nemenoff; Amy M Meyer; Tyler M Hudish; Anthony B Mozer; Amy Snee; Shuh Narumiya; Robert S Stearman; Robert A Winn; Mary Weiser-Evans; Mark W Geraci; Robert L Keith
Journal:  Cancer Prev Res (Phila)       Date:  2008-10

Review 8.  The immunoregulatory mechanisms of carcinoma for its survival and development.

Authors:  Caigan Du; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-01-21

9.  CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast.

Authors:  Tsengelmaa Jamiyan; Hajime Kuroda; Rin Yamaguchi; Akihito Abe; Mitsuhiro Hayashi
Journal:  Virchows Arch       Date:  2020-06-30       Impact factor: 4.064

Review 10.  Prognostic factors in resected lung carcinomas.

Authors:  Keith M Kerr; Marianne C Nicolson
Journal:  EJC Suppl       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.